In comparison, studies with over 2000 breast cancer subjects and 1100 lung cancer subjects found mutations in the juxtamembrane domain of HER1 in 0% and 0.07% of cases, respectively [78–81]. This evidence concerns the gene EGFR and lung carcinoma.